Advertisement
Screener

OMEROS CORP (OMER) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

OMEROS CORP Research and Development Expense

OMEROS CORP (OMER) reported Research and Development Expense of $13.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12

  • OMEROS CORP research and development expense for the quarter ending 2026-06-30 was $13.80M, a 37.31% decline year-over-year.
  • OMEROS CORP research and development expense for the quarter ending 2026-03-31 was $13.36M, a 43.98% decline year-over-year.
  • OMEROS CORP research and development expense for the quarter ending 2025-12-31 was $19.45M, a 16.61% decline year-over-year.
  • OMEROS CORP research and development expense for the quarter ending 2025-09-30 was $15.99M, a 33.59% decline year-over-year.
  • OMEROS CORP research and development expense for fiscal 2025 was $81.30M, a 31.98% decline from fiscal 2024.
  • OMEROS CORP research and development expense for fiscal 2024 was $119.52M, a 4.05% increase from fiscal 2023.
  • OMEROS CORP research and development expense for fiscal 2023 was $114.87M, a 1.91% increase from fiscal 2022.
  • OMEROS CORP research and development expense for fiscal 2022 was $112.72M, a 5.10% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filed
2026-06-30$13.80M
10-Q · filed 2026-08-12
$27.16M
10-Q · filed 2026-08-12
$46.60M
derived: sum of 3 quarters · filed 2026-08-12
$62.60M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$13.36M
10-Q · filed 2026-05-13
$32.80M
derived: sum of 2 quarters · filed 2026-05-13
$48.80M
derived: sum of 3 quarters · filed 2026-05-13
$70.81M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$19.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$35.44M
derived: sum of 2 quarters · filed 2026-03-31
$57.45M
derived: sum of 3 quarters · filed 2026-08-12
$81.30M
10-K · filed 2026-03-31
2025-09-30$15.99M
10-Q · filed 2025-11-13
$38.00M
derived: sum of 2 quarters · filed 2026-08-12
$61.85M
10-Q · filed 2025-11-13
$85.17M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$22.01M
10-Q · filed 2026-08-12
$45.85M
10-Q · filed 2026-08-12
$69.17M
derived: sum of 3 quarters · filed 2026-08-12
$93.26M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$23.85M
10-Q · filed 2026-05-13
$47.17M
derived: sum of 2 quarters · filed 2026-05-13
$71.25M
derived: sum of 3 quarters · filed 2026-05-13
$116.60M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$23.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$47.40M
derived: sum of 2 quarters · filed 2026-03-31
$92.75M
derived: sum of 3 quarters · filed 2026-03-31
$119.52M
10-K · filed 2026-03-31
2024-09-30$24.08M
10-Q · filed 2025-11-13
$69.43M
derived: sum of 2 quarters · filed 2025-11-13
$96.20M
10-Q · filed 2025-11-13
$125.09M
derived: sum of 4 quarters · filed 2026-03-31
2024-06-30$45.35M
10-Q · filed 2025-08-14
$72.12M
10-Q · filed 2025-08-14
$101.01M
derived: sum of 3 quarters · filed 2026-03-31
$132.74M
derived: sum of 4 quarters · filed 2026-03-31
2024-03-31$26.77M
10-Q · filed 2025-05-15
$55.66M
derived: sum of 2 quarters · filed 2026-03-31
$87.39M
derived: sum of 3 quarters · filed 2026-03-31
$117.03M
derived: sum of 4 quarters · filed 2026-03-31
2023-12-31$28.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$60.62M
derived: sum of 2 quarters · filed 2026-03-31
$90.26M
derived: sum of 3 quarters · filed 2026-03-31
$114.87M
10-K · filed 2026-03-31
2023-09-30$31.73M
10-Q · filed 2024-11-13
$61.37M
derived: sum of 2 quarters · filed 2024-11-13
$85.98M
10-Q · filed 2024-11-13
$112.53M
derived: sum of 4 quarters · filed 2025-03-31
2023-06-30$29.64M
10-Q · filed 2024-08-07
$54.25M
10-Q · filed 2024-08-07
$80.80M
derived: sum of 3 quarters · filed 2025-03-31
$119.37M
derived: sum of 4 quarters · filed 2025-03-31
2023-03-31$24.61M
10-Q · filed 2024-05-15
$51.16M
derived: sum of 2 quarters · filed 2025-03-31
$89.73M
derived: sum of 3 quarters · filed 2025-03-31
$113.24M
derived: sum of 4 quarters · filed 2025-03-31
2022-12-31$26.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$65.12M
derived: sum of 2 quarters · filed 2025-03-31
$88.63M
derived: sum of 3 quarters · filed 2025-03-31
$112.72M
10-K · filed 2025-03-31
2022-09-30$38.57M
10-Q · filed 2023-11-09
$62.08M
derived: sum of 2 quarters · filed 2023-11-09
$86.17M
10-Q · filed 2023-11-09
$116.50M
derived: sum of 4 quarters · filed 2024-04-01
2022-06-30$23.52M
10-Q · filed 2023-08-09
$47.60M
10-Q · filed 2023-08-09
$77.93M
derived: sum of 3 quarters · filed 2024-04-01
$103.75M
derived: sum of 4 quarters · filed 2024-04-01
2022-03-31$24.09M
10-Q · filed 2023-05-09
$54.41M
derived: sum of 2 quarters · filed 2024-04-01
$80.23M
derived: sum of 3 quarters · filed 2024-04-01
$110.36M
derived: sum of 4 quarters · filed 2024-04-01
2021-12-31$30.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$56.15M
derived: sum of 2 quarters · filed 2024-04-01
$86.27M
derived: sum of 3 quarters · filed 2024-04-01
$118.78M
10-K · filed 2024-04-01
2021-09-30$25.82M
10-Q · filed 2022-11-09
$27.06M
10-Q · filed 2021-11-09
$55.94M
derived: sum of 2 quarters · filed 2022-11-09
$88.45M
10-Q · filed 2022-11-09
$91.36M
10-Q · filed 2021-11-09
$111.70M
derived: sum of 4 quarters · filed 2023-03-13
2021-06-30$30.13M
10-Q · filed 2022-08-09
$30.94M
10-Q · filed 2021-08-09
$62.63M
10-Q · filed 2022-08-09
$64.31M
10-Q · filed 2021-08-09
$85.88M
derived: sum of 3 quarters · filed 2023-03-13
$117.20M
derived: sum of 4 quarters · filed 2023-03-13
2021-03-31$32.50M
10-Q · filed 2022-05-10
$33.36M
10-Q · filed 2021-05-10
$55.76M
derived: sum of 2 quarters · filed 2023-03-13
$87.07M
derived: sum of 3 quarters · filed 2023-03-13
$111.20M
derived: sum of 4 quarters · filed 2023-03-13
2020-12-31$23.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13
$54.57M
derived: sum of 2 quarters · filed 2023-03-13
$78.70M
derived: sum of 3 quarters · filed 2023-03-13
$107.61M
10-K · filed 2023-03-13
$110.82M
10-K · filed 2021-03-01
2020-09-30$31.32M
10-Q · filed 2021-11-09
$55.45M
derived: sum of 2 quarters · filed 2021-11-09
$84.36M
10-Q · filed 2021-11-09
$121.58M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30$24.13M
10-Q · filed 2021-08-09
$53.04M
10-Q · filed 2021-08-09
$90.26M
derived: sum of 3 quarters · filed 2022-03-01
$114.00M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$28.91M
10-Q · filed 2021-05-10
$66.13M
derived: sum of 2 quarters · filed 2022-03-01
$89.87M
derived: sum of 3 quarters · filed 2022-03-01
$108.98M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$37.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$60.96M
derived: sum of 2 quarters · filed 2022-03-01
$80.07M
derived: sum of 3 quarters · filed 2022-03-01
$106.32M
10-K · filed 2022-03-01
$109.70M
10-K · filed 2020-03-02
2019-09-30$23.75M
10-Q · filed 2020-11-09
$42.85M
derived: sum of 2 quarters · filed 2020-11-09
$69.11M
10-Q · filed 2020-11-09
$94.56M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$19.11M
10-Q · filed 2020-08-10
$45.36M
10-Q · filed 2020-08-10
$70.81M
derived: sum of 3 quarters · filed 2021-03-01
$97.67M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$26.25M
10-Q · filed 2020-05-11
$51.70M
derived: sum of 2 quarters · filed 2021-03-01
$78.56M
derived: sum of 3 quarters · filed 2021-03-01
$97.97M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$25.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$52.31M
derived: sum of 2 quarters · filed 2021-03-01
$71.72M
derived: sum of 3 quarters · filed 2021-03-01
$89.86M
10-K · filed 2021-03-01
2018-09-30$26.86M
10-Q · filed 2019-11-12
$46.27M
derived: sum of 2 quarters · filed 2019-11-12
$64.41M
10-Q · filed 2019-11-12
$79.80M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30$19.41M
10-Q · filed 2019-08-08
$37.55M
10-Q · filed 2019-08-08
$52.94M
derived: sum of 3 quarters · filed 2020-03-02
$67.77M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31$18.14M
10-Q · filed 2019-05-09
$33.53M
derived: sum of 2 quarters · filed 2020-03-02
$48.36M
derived: sum of 3 quarters · filed 2020-03-02
$61.50M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31$15.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$30.22M
derived: sum of 2 quarters · filed 2020-03-02
$43.36M
derived: sum of 3 quarters · filed 2020-03-02
$55.60M
10-K · filed 2020-03-02
2017-09-30$14.84M
10-Q · filed 2018-11-08
$27.97M
derived: sum of 2 quarters · filed 2018-11-08
$40.21M
10-Q · filed 2018-11-08
$52.75M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$13.14M
10-Q · filed 2018-08-09
$25.38M
10-Q · filed 2018-08-09
$37.92M
derived: sum of 3 quarters · filed 2019-03-01
$50.41M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$12.24M
10-Q · filed 2018-05-10
$24.78M
derived: sum of 2 quarters · filed 2019-03-01
$37.27M
derived: sum of 3 quarters · filed 2019-03-01
$47.51M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$12.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$25.03M
derived: sum of 2 quarters · filed 2019-03-01
$35.27M
derived: sum of 3 quarters · filed 2019-03-01
$50.70M
10-K · filed 2019-03-01
2016-09-30$12.49M
10-Q · filed 2017-11-09
$22.72M
derived: sum of 2 quarters · filed 2017-11-09
$38.16M
10-Q · filed 2017-11-09
$53.05M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30$10.23M
10-Q · filed 2017-08-08
$25.66M
10-Q · filed 2017-08-08
$40.56M
derived: sum of 3 quarters · filed 2018-03-01
$53.83M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31$15.43M
10-Q · filed 2017-05-10
$30.33M
derived: sum of 2 quarters · filed 2018-03-01
$43.59M
derived: sum of 3 quarters · filed 2018-03-01
$54.49M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31$14.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
$28.16M
derived: sum of 2 quarters · filed 2018-03-01
$39.06M
derived: sum of 3 quarters · filed 2018-03-01
$48.38M
10-K · filed 2018-03-01
2015-09-30$13.26M
10-Q · filed 2016-11-09
$24.16M
derived: sum of 2 quarters · filed 2016-11-09
$33.48M
10-Q · filed 2016-11-09
$45.23M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$10.90M
10-Q · filed 2016-08-09
$20.22M
10-Q · filed 2016-08-09
$31.97M
derived: sum of 3 quarters · filed 2017-03-16
$43.74M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$9.32M
10-Q · filed 2016-05-10
$21.07M
derived: sum of 2 quarters · filed 2017-03-16
$32.84M
derived: sum of 3 quarters · filed 2017-03-16
$45.25M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$11.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$23.52M
derived: sum of 2 quarters · filed 2017-03-16
$35.93M
derived: sum of 3 quarters · filed 2017-03-16
$47.95M
10-K · filed 2017-03-16
2014-09-30$11.77M
10-Q · filed 2015-11-09
$24.18M
derived: sum of 2 quarters · filed 2015-11-09
$36.20M
10-Q · filed 2015-11-09
$46.38M
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30$12.41M
10-Q · filed 2015-08-10
$24.42M
10-Q · filed 2015-08-10
$34.61M
derived: sum of 3 quarters · filed 2016-03-15
$44.03M
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31$12.02M
10-Q · filed 2015-05-11
$22.20M
derived: sum of 2 quarters · filed 2016-03-15
$31.62M
derived: sum of 3 quarters · filed 2016-03-15
$41.19M
derived: sum of 4 quarters · filed 2016-03-15
2013-12-31$10.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
$19.61M
derived: sum of 2 quarters · filed 2016-03-15
$29.17M
derived: sum of 3 quarters · filed 2016-03-15
$36.30M
10-K · filed 2016-03-15
2013-09-30$9.42M
10-Q · filed 2014-11-10
$18.98M
derived: sum of 2 quarters · filed 2014-11-10
$26.11M
10-Q · filed 2014-11-10
$35.47M
derived: sum of 4 quarters · filed 2015-03-16
2013-06-30$9.56M
10-Q · filed 2014-08-11
$16.69M
10-Q · filed 2014-08-11
$26.05M
derived: sum of 3 quarters · filed 2015-03-16
$33.81M
derived: sum of 4 quarters · filed 2015-03-16
2013-03-31$7.13M
10-Q · filed 2014-05-12
$16.48M
derived: sum of 2 quarters · filed 2015-03-16
$24.25M
derived: sum of 3 quarters · filed 2015-03-16
$31.80M
derived: sum of 4 quarters · filed 2015-03-16
2012-12-31$9.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16
$17.12M
derived: sum of 2 quarters · filed 2015-03-16
$24.68M
derived: sum of 3 quarters · filed 2015-03-16
$31.92M
10-K · filed 2015-03-16
2012-09-30$7.76M
10-Q · filed 2013-11-07
$15.32M
derived: sum of 2 quarters · filed 2013-11-07
$22.57M
10-Q · filed 2013-11-07
$31.46M
derived: sum of 4 quarters · filed 2014-03-13
2012-06-30$7.56M
10-Q · filed 2013-08-09
$14.80M
10-Q · filed 2013-08-09
$23.70M
derived: sum of 3 quarters · filed 2014-03-13
$29.02M
derived: sum of 4 quarters · filed 2014-03-13
2012-03-31$7.25M
10-Q · filed 2013-05-09
$16.14M
derived: sum of 2 quarters · filed 2014-03-13
$21.46M
derived: sum of 3 quarters · filed 2014-03-13
$25.54M
derived: sum of 4 quarters · filed 2014-03-13
2011-12-31$8.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13
$14.22M
derived: sum of 2 quarters · filed 2014-03-13
$18.29M
derived: sum of 3 quarters · filed 2014-03-13
$23.72M
10-K · filed 2014-03-13
2011-09-30$5.32M
10-Q · filed 2012-11-09
$9.40M
derived: sum of 2 quarters · filed 2012-11-09
$14.82M
10-Q · filed 2012-11-09
2011-06-30$4.08M
10-Q · filed 2012-08-07
$9.50M
10-Q · filed 2012-08-07
2011-03-31$5.42M
10-Q · filed 2012-05-10
2010-12-31$23.46M
10-K · filed 2013-03-18
2009-12-31$16.93M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82